Invitrogen™ Finotonlimab Recombinant Monoclonal Antibody

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Finotonlimab, also known as SCT-I10A, is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, which plays a critical role in downregulating the immune system and promoting self-tolerance by suppressing T-cell inflammatory activity. The gene PDCD1, also known as PD-1 or CD279, encodes Programmed Cell Death Protein 1, a crucial immune checkpoint receptor expressed on T cells and other immune cells. Located on chromosome 2q37.3, PDCD1 consists of five exons. PD-1 is a type I transmembrane protein within the CD28/CTLA-4 superfamily and functions primarily to inhibit immune responses, thus maintaining peripheral tolerance and preventing autoimmune reactions. Upon binding to its ligands, PD-L1 and PD-L2, expressed on tumor cells and other tissues, PD-1 mediates the suppression of T-cell activity, inducing apoptosis in antigen-specific T cells while sparing regulatory T cells, contributing significantly to immune evasion by tumors.